Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Soleus Capital

Investor type Private Equity Firm
Founders Guy Levy

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 40
Average round size
info
The average size of a deal this fund participated in
$89M
Portfolio companies 30
Rounds per year 10.00
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.23
Exits 12
Key employees Soon
Stages of investment
Early Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Medical
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Soleus Capital:
Typical Co-investors
Soleus Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Soleus Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Adler Chomsky & Warsawasky Israel, Tel Aviv, Tel Aviv District
Alpha Edison California, Los Angeles, United States
Arcus Ventures New York, New York, United States
Brill Capital -
Currency Capital California, Los Angeles, United States
Drayton Park Capital Pennsylvania, Radnor, United States
Growth Capital Fund by Co-Hub Lagos, Lagos, Nigeria
Manifold Partners Francisco, North Carolina, United States
New Age Capital New York, New York, United States
P3 Technology Partners -
Pathway Capital Management California, Irvine, United States
Tianjin Wanrong Wenfu Zichan Guanli Zhongxin (Youxian Hehuo) China, Guangdong, Tianjin
Topline Capital California, United States, Villa Park
Tracxn Syndicate Bangalore, India, Karnataka
Washington Research Foundation. Seattle, United States, Washington
Wutong Ideal Capital Management Beijing, Beijing, China
Yihui Touzi China, Guangdong, Shenzhen

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

BioAtla

Biotechnology
Health Care
Medical
$65M04 Nov 2022 San Diego, California, United States

RayzeBio

Biotechnology
Health Care
Medical Device
Pharmaceutical
$160M13 Sep 2022 San Diego, California, United States

Celcuity

Biotechnology
Health Care
Health Diagnostics
Therapeutics
$100M16 May 2022 Minnesota, United States

LimFlow SA

Emergency Medicine
Health Care
Medical Device
$42M05 Apr 2022 Paris, Ile-de-France, France

Beta Bionics

Biotechnology
Diabetes
Medical Device
$57M17 Feb 2022 Boston, Massachusetts, United States

Parse Biosciences

Bioinformatics
Biotechnology
Genetics
Life Science
$41M15 Feb 2022 Seattle, Washington, United States

Freenome

Biotechnology
Health Care
Health Diagnostics
Personal Health
$300M07 Dec 2021 South San Francisco, California, United States

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
$75M03 Nov 2021 Atlanta, Georgia, United States

BioAtla

Biotechnology
Health Care
Medical
$75M29 Sep 2021 San Diego, California, United States
News
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Soleus Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: